FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia

Regeneron (REGN) PRALUEN Panel Commentary Could Result in Narrower-Than-Expected Labeling, BMO Capital Says

June 10, 2015 7:48 AM EDT

BMO Capital analyst Jim Birchenough reiterated a Market Perform rating and $381 price target on Regeneron Pharma (NASDAQ: REGN) following yesterday's FDA panel review of PRALUEN.

Birchenough commented, "While the ultimate vote was positive and should support approval, we believe that panel member commentary could result in... More

Regeneron (REGN) Resumes Trading Up 1%

June 9, 2015 6:50 PM EDT

Regeneron (NASDAQ: REGN) resumed trading up 1% after confirming FDA panel backing of Praluent injection.

... More